Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design

Depression and Anxiety

Volumn 17, Issue 1, 2003, Pages 10-18

  Baker, C Bruce ^a   Woods, Scott W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression, SSRI; Dose response; Study design

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL PRACTICE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HUMANS; PATIENT DROPOUTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0037284196     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.10076     Document Type: Article

References (29)

1. Amin M, Lehmann H, et al. 1989. A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull 25:164-167.
2. Baker BC, Tweedie R, Duval S, Woods SW. 2003. Evidence that the SSRI dose response in treating major depression should be reassessed; A meta-analysis. Depress Anxiety 17:1-9.
3. Benkert O, Szegedi A, et al. 1997. Dose escalation vs. continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 95:288-296.
4. Corruble E, Guelfi JD. 2000. Does increasing dose improve efficacy in patients with poor antidepressant response: A review. Acta Psychiatr Scand 101:343-48.
5. Dornseif BE, Dunlop SR, et al. 1989. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 25:71-79.
6. Dunner DL, Dunbar GC. 1992. Optimal dose regimen for paroxetine. J Clin Psychiatry 53:21-26.
7. Ekholm BP, Terrance LF, et al. 1990. Dose-response: relating doses and plasma levels to efficacy and adverse experiences. In: Berry DA, editor. Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker, Inc. p 117-138.
8. Emilien G, van Meurs W, et al. 2000. The dose-response relationship in Phase I clinical trials and beyond: Use, meaning, and assessment. Pharmacol Ther 88:33-58.
9. Fabre LF, Abuzzahab FS, et al. 1995. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo. Biol Psychiatry 38:592-602.
10. Fabre LF, Putman HP. 1987. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 48:406-408.
11. Fava M, Rosenbaum JF, et al. 1994. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study. Am J Psychiatry 151:1372-1374.
12. Girard P, Laporte-Simitsidis S, et al., (1995. Influence of confounding factors on designs for dose-effect relationship estimates. Stat Med 14:987-1005.
13. Katona CLE. 1995. Refractory depression: a review with particular reference to the use of lithium augmentation. Eur Neuropsychopharmacol (Suppl 5):109-113.
14. Laporte-Simitsidis S, Mismetti P, et al. 1995. Influence of confounding factors on designs for dose-effect relationship estimates. Stat Med 14:987-1005.
15. Leon AC. 2001. Measuring onset of antidepressant action in clinical trials: An overview of definitions and methodology. J Clin Psychiatry 62:12-16.
16. Mallinckrodt CH, Clark WS, et al. 2001. Accounting for dropout bias using mixed-effects models. J Biopharmaceut Stat 11:9-21.
17. Nierenberg AA, McLean NE, et al. 1995. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152:1500-1503.
18. Preskorn SH, Lane RM. 1995. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 10:129-141.
19. Quitkin FM, McGrath PJ, et al. 1996. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 53:785-92.
20. Schmidt R. 1988. Dose-finding studies in clinical drug development. Eur J Clin Pharmacol 34;15-19.
21. Schweizer E, Rickels K, et al. 1990. What constitutes an adequate antidepressant trial for fluoxetine. J Clin Psychiatry 51:8-11.
22. Sheiner LB, Beal SL, et al. 1989. Designs for dose-ranging. Clin Pharmacol Ther 46:63-77.
23. Sheiner LB, Hashimoto Y, et al. 1991. A simulation study comparing designs for dose ranging. Stat Med 10:303-321.
24. Spilker B. 1991a. Combining efficacy data from multiple trials, chap 116. Guide to clinical trials. B. Spilker. New York: Raven Press.
25. Spilker B. 1991b. Guide to clinical trials. New York: Raven Press.
26. Thase ME, Rush AJ. 1995. Treatment-resistant depression. In: Bloom FE, Kupfer DJ. Psychopharmacology: The fourth generation of progress. New York: Raven Press. p 1081-1097.
27. Walczak DD, Apter JT, et al. 1996. The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 8:139-151.
28. Wernicke JF, Dunlop SR, et al. 1988. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24:183-188.
29. Wernicke JF, Dunlop SR, et al. 1987. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 23:16416-16418.